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Background: Perfluoroalkyl substances (PFASs) are a group of highly persistent chemicals that are widespread
contaminants in wildlife and humans. Exposure to PFAS affects thyroid homeostasis in experimental animals and
possibly in humans. The objective of this study was to examine the association between plasma concentrations of
PFASs and thyroid stimulating hormone (TSH) among pregnant women.
Methods: A total of 903 pregnant women who enrolled in the Norwegian Mother and Child Cohort Study from
2003 to 2004 were studied. Concentrations of thirteen PFASs and TSH were measured in plasma samples collected
around the 18th week of gestation. Linear regression models were used to evaluate associations between PFASs
and TSH.
Results: Among the thirteen PFASs, seven were detected in more than 60% of samples and perfluorooctane
sulfonate (PFOS) had the highest concentrations (median, 12.8 ng/mL; inter-quartile range [IQR], 10.1 -16.5 ng/mL).
The median TSH concentration was 3.5 (IQR, 2.4 - 4.8) μIU/mL. Pregnant women with higher PFOS had higher TSH
levels. After adjustment, with each 1 ng/mL increase in PFOS concentration, there was a 0.8% (95% confidence
interval: 0.1%, 1.6%) rise in TSH. The odds ratio of having an abnormally high TSH, however, was not increased, and
other PFASs were unrelated to TSH.
Conclusions: Our results suggest an association between PFOS and TSH in pregnant women that is small and may
be of no clinical significance.
Keywords: Perfluorinated alkyl substances, Thyroid stimulating hormone, Pregnant women, The Norwegian Mother
and child cohort study, MoBaBackground
Perfluoroalkyl substances (PFASs) are a group of man-made
chemicals with a fully fluorinated hydrophobic linear
carbon chain attached to a hydrophilic functional group
[1]. Being both lipo- and hydrophobic, they are widely used
in industry to make products that are resistant to heat, oil,
stains, grease and water [2]. Furthermore, the very high
strength of the carbon-fluoride bonds makes PFASs highly
stable and resistant to environmental degradation [3]. As* Correspondence: wangy13@niehs.nih.gov
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reproduction in any medium, provided the ora consequence, they are widespread in the environment,
wildlife, and humans [4]. Diet is thought to be the main
exposure route of PFASs for humans [5,6], and ingestion
of dust from indoor environments may also contribute to
the internal dose [7]. PFASs may act as endocrine disruptors
by altering the activity of endogenous hormones [8].
Thyroid hormones play an essential role in ensuring
a healthy pregnancy and normal fetal growth and
development. Fetuses depend on the mother’s supply of
T4 entirely during the first trimester, and continue to rely
on it to varying degrees throughout the pregnancy [9,10].
At birth, around 30% of thyroid hormone is from the
mother [11]. Alterations of maternal thyroid hormonetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for the mother and offspring [12,13].
In pregnant rats and their offspring, treatment with
perfluorooctane sulfonate (PFOS) can cause a decrease
in total plasma thyroxine (T4) and triiodothyronin (T3)
[14-17]. In humans, some PFASs have been associated
with elevated T4 levels [18-20] and higher exposure to
perfluorooctanoic acid (PFOA) or PFOS was related to
increased risk of thyroid disease [21]. Other studies,
however, did not find any association between PFASs
and thyroid function [22-24]. Findings have generally
been inconsistent and most studies were carried out in
non-pregnant adults. One study on PFAS in pregnancy,
however, showed an association of maternal pregnancy
serum PFOA with increased cord TSH [25].
Given the potential association between PFASs and
thyroid hormones, concern arises about whether PFAS
exposure may disrupt maternal thyroid hormone homeo-
stasis during pregnancy. In the present study, our aim was
to examine the relationship between PFASs and TSH as a




The Norwegian Mother and Child Cohort Study (MoBa)
is a prospective population-based pregnancy cohort study
conducted by the Norwegian Institute of Public Health
[26]. Participants were recruited from all over Norway
from 1999–2008, and 38.5% of invited women consented
to participate. They received a postal invitation and the
baseline questionnaire in weeks 13–17 of pregnancy,
together with an appointment for an ultrasound scan in
week 17–18 of pregnancy. The Regional Committee for
Medical Research and the Norwegian Data Inspectorate
approved the study, and signed informed consent was
obtained from each participant.
The subjects in the present study were from a previous
case–control analysis of subfecundity in a subset of MoBa
women [27]. These subjects (N = 950) were selected
from MoBa participants who enrolled in 2003 and 2004,
delivered a live born child and provided a blood sample
around week 17–18 of gestation. Among these eligible
women, 400 subfecund women (who planned their preg-
nancy and reported time to pregnancy >12 months) were
selected randomly. Additionally, 550 control women
were selected at random. More details can be found in
the previous publication [27]. Twenty of the 950 women
reported a thyroid abnormality and were excluded from
the main analyses.
Assessment of PFASs
Blood specimens were collected at enrollment [28], and
the mean gestational age at blood draw was 18 weeks.Up to thirteen PFASs were measured in plasma using
high-performance liquid chromatography/tandem mass
spectrometry at the Norwegian Institute of Public Health;
these were PFOS, PFOA, perfluoroheptanoic acid (PFHpA),
perfluorononanoic acid (PFNA), perfluorodecanoic acid
(PFDA), perfluoroundecanoic acid (PFUnDA), perfluoro-
dodecanoic acid (PFDoDA), perfluorotridecanoic acid
(PFTrDA), perfluorotetradecanoic acid (PFTeDA), per-
fluorobutanoic acid (PFBA), perfluorohexane sulfonic
acid (PFHxS), perfluoroheptane sulfonic acid (PFHpS),
and perfluorooctane sulfonamide (PFOSA). A detailed
description of the analytic method has been published [29].
Among the substances measured, PFOA, PFOS, PFDA,
PFHpS, PFHxS, PFNA, and PFUnDA were detected in
more than 69% of samples; the six other PFASs were
detected in less than 25% of the samples and were not
included in the subsequent analysis. The limit of quanti-
fication (LOQ) was 0.1 ng/ml for PFBA and 0.05 ng/ml
for all others. For the seven most frequently detected
PFASs, values below the LOQ were replaced by the LOQ
divided by the square root of 2. The intra-assay coefficients
of variation (CVs) of all seven PFASs were < 10% except
PFUnDA (13.1%), and the inter-assay CVs of all seven
PFASs were < 15% except PFUnDA (18.7%) and PFHpS
(25.2%).
Assessment of TSH
Plasma TSH measurements were performed on the same
plasma specimen using an immunoassay (MILLIPLEX
map kit, Millipore Corporation, Billerica, MA, USA) on
the LiquiChip 200 Workstation (Qiagen Inc., Germantown,
MD) at the National Institute of Environmental Health
Sciences, USA. Duplicate plasma TSH concentrations
were measured for each sample and the mean was used in
the analysis. The minimum detectable concentration was
0.01 μIU/mL. Both the intra-assay CV and inter-assay CV
were <10%.
Statistical analysis
The main outcome, TSH, was natural logarithm trans-
formed (ln-transformed) to obtain a normal distribution.
As there was no statistically significant difference in mean
ln-TSH concentrations between the subfecund subjects
and the control subjects (1.22 vs 1.19 μIU/mL, student
t-test P = 0.34), we combined them in the subsequent
analysis. Scatter plots showed approximately linear rela-
tionships between PFASs and ln-TSH, thus we used linear
regression models to examine PFASs and ln-TSH and
applied weighted methods (PROC SURVEYMEANS,
PROC SURVEYREG and SURVEYLOGISTIC in SAS 9.2,
Cary, NC, USA) to adjust for selection into the previous
case–control study [30]. Each PFAS was examined in a
separate model and was represented either as a continu-
ous variable, or categorically based on quartiles. Logistic
Table 1 Characteristics of the 903 subjects
Mean (SD) Range
Age (yrs) 30 (4) 18 - 44
Gestational age (weeks) 18 (2) 12 - 37
Pre-pregnancy BMI (kg/m2) 25 (7) 15 – 45
HDL (mg/dL) 67 (12) 39 - 106
Total seafood intake (times/week) 5 (5.9) 0 - 56
Inter-pregnancy interval (months) 48 (37) 0 - 245
Duration of breast-feeding a
previous child (months)









< High school 9
High school 33
Some college 41
≥ 4-year college 17
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omized as at or above the 95th percentile (7.5 μIU/mL) or
below.
We identified potentially confounding factors based on
the literature [6,25,31,32]. They included age, gestational
age at blood draw, pre-pregnancy body mass index
(BMI, kg/m2), parity, smoking during pregnancy, interval
between previous birth and current pregnancy, duration
of breast-feeding a previous child, total seafood intake at
mid-pregnancy, and plasma concentrations of high-density
lipoprotein (HDL) and albumin. With the exception of
age and gestational age, which were included a priori,
confounders for inclusion in the models were identified
using bivariate linear regression models with the exposure
and outcome variables. Only those variables associated
with any PFAS and also with TSH (P < 0.1) were included
in the final models. Twenty-seven women were excluded
because of missing data on covariates. Additional adjust-
ment for consumption of fatty fish or use of medications
that can affect thyroid hormone levels had essentially
no effect on the results (not shown). In a sensitivity
analysis we also fit a logistic model of self-reported thyroid
abnormality during pregnancy (n = 20) or not (n =903)
in relation to each PFAS. We also repeated the linear
regression models of TSH after stratifying according to
whether the women were in the control or subfecund
group.Results
Study population and plasma concentrations of PFASs
and TSH
The average maternal age was 30 years (standard deviation
[SD] = 4) and ranged from 18 to 44 years (Table 1). Almost
all of the women (97%) were in the second trimester at
the time of the blood draw (average, 18 weeks; range,
12–37 weeks). Half of the women were nulliparous.
Among the seven most frequently detected PFASs, the
median concentration was greatest for PFOS (12.8 ng/mL;
inter-quartile range [IQR], 10.1 -16.5 ng/mL), followed
by PFOA, PFHxS, PFNA, PFUnDA, PFHpS, and PFDA
(Table 2). Moderate positive correlations were found
between concentrations of PFOS and PFOA (r = 0.66,
P < 0.001), and between PFOS and PFHpS (r = 0.69,
P < 0.001). The median blood concentration of TSH was
3.5 (IQR: 2.4, 4.8) μIU/mL.
Based on bivariate linear regression models, all PFAS
concentrations in nulliparous women were higher than
in parous women (P < 0.1). Among parous women,
those who experienced longer inter-pregnancy inter-
val had higher concentrations of PFASs, except PFHxS
(P < 0.05). Most PFASs (all except PFHxS and PFOA)
were positively associated with seafood intake in times/
week (P < 0.05).Associations between PFASs and TSH
Among the seven PFASs, PFHpS, PFNA, and PFOS were
positively associated with TSH levels (Table 3). Adjustment
for confounders reduced the magnitude and statistical
significance of associations between PFHpS and TSH, and
PFNA and TSH. Only PFOS remained statistically signifi-
cant after adjustment (P = 0.03), with a slight attenuation
in the coefficient (β). To express the coefficients as percent
change in TSH (original units), per ng/mL increase in
PFOS, we calculated 100 × [exp (β) – 1]. For example,
the adjusted β of 0.008 for PFOS means a 100 × [exp
(0.008) – 1] or 0.8% (95% CI: [0.1%, 2.0%]) increase in
TSH per ng/mL increase in PFOS.
Next, to examine the relationship between categorical
PFASs and TSH levels we divided PFASs into quartiles
and used the first quartile as the reference group. Figure 1
shows that there was an increasing trend in TSH across
the quartiles of PFOS, but only women in the third and
fourth quartiles had significantly higher TSH levels
compared with the reference group.
When TSH was dichotomized (TSH ≥ 7.5 vs < 7.5 μIU/
mL) in logistic models, no significant association with
any PFAS emerged, whether the latter was considered
either as a continuous or categorical variable. In addition,
there were no significant associations found between PFASs
and self-reported thyroid abnormality.
Among the women who were selected as controls from
the MoBa cohort, we observed very similar results. The
Table 2 Distributions of plasma concentrations of PFASs (ng/mL) and TSH (μIU/mL)
PFASs * % > LOQ Geometric mean (95% CI) 25th percentile Median 75th percentile Maximum
PFDA 69 0.09 (0.08, 0.09) 0.04 0.09 0.15 1.77
PFHpS 88 0.12 (0.11, 0.12) 0.08 0.13 0.18 0.97
PFHxS 99 0.62 (0.59, 0.64) 0.43 0.60 0.84 21.74
PFNA 99 0.37 (0.36, 0.39) 0.28 0.39 0.51 3.01
PFOA 100 2.13 (2.07, 2.20) 1.57 2.15 2.95 13.99
PFOS 100 12.77 (12.45, 13.10) 10.13 12.81 16.49 104.18
PFUnDA 94 0.20 (0.19, 0.21) 0.14 0.22 0.32 1.17
TSH 100 3.39 (3.25, 3.49) 2.44 3.52 4.81 18.64
* N = 903. For values of PFASs below LOQ, LOQs divided by square root of 2 were imputed and used in the calculations of statistics (PROC SURVEYMEANS).
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and TSH (adjusted β = 0.008 [95% CI: 0.001, 0.016]).
Among women in the subfecund group, the association
was inverse and non-significant (β = −0.0016, 95% CI:
[−0.008, 0.005]).Discussion
The precise classification of suboptimal thyroid status
requires measurement of more than one hormone.
For example, low free T4 with normal TSH reflects
hypothyroxinemia [33]. Elevated TSH with normal free T4
reflects subclinical hypothyroidism. In the present study,
where we used TSH by itself as a screening measure, we
saw no indication that PFOS was associated with abnor-
mally high TSH. Rather, the data suggested an association
within the normal range of TSH, and in the absence of a
measure of free T4, the clinical importance is unclear.
Because we saw no association with abnormally high TSH
nor with the presence of a history of thyroid disease, our
generally null results were reassuring and consistent with
a subtle association that may reflect only a biochemical
curiosity. However, the possibility exists that our study did
not have enough statistical power to detect a small associ-
ation with abnormally high TSH, and that there is a small
effect on public health (increased hypothyroidism).Table 3 Unadjusted and adjusted β and 95% confidence
intervals for associations between PFASs and TSH
(ln-transformed)
PFASs (ng/mL) Unadjusted β (N = 903) Adjusted β (N = 903) *
PFDA 0.246 (−0.258, 0.749) 0.060 (−0.458, 0.578)
PFHpS 0.537 (0.142, 0.932) 0.299 (−0.113, 0.710)
PFHxS 0.026 (−0.031, 0.084) 0.013 (−0.043, 0.070)
PFNA 0.251 (0.070, 0.432) 0.165 (−0.023, 0.353)
PFOA 0.029 (−0.008, 0.066) −0.0001 (−0.045, 0.044)
PFOS 0.012 0.005, 0.019) 0.008 (0.001, 0.016)
PFUnDA 0.194 (−0.069, 0.457) 0.080 (−0.200, 0.360)
* Models adjusted for maternal age, gestational age at blood draw, HDL
concentrations, total seafood intake, parity and inter-pregnancy interval.In a study of 44 Korean pregnant women with serum
measures of PFAS and several thyroid hormones in cord
blood [25], inverse associations were found between
maternal PFOS and neonatal total T3, and between
maternal perfluorotridecanoic acid and neonatal total
T3 and T4. In addition, maternal PFOA was associated
with increased cord TSH (n = 31). However, the median
maternal PFOS concentration (2.93 [IQR: 2.08, 4.36]
ng/mL) was much lower than that in our study. In a
case–control study of hypothyroxinemia among Canadian
pregnant women (96 cases, 175 controls), the authors
found no association with serum concentrations of PFOA,
PFOS and PFHxS. In that study, the geometric mean of
PFOS (7.39 ng/mL) [23] was lower than among women in
the present study (12.77 ng/mL).
In animal experiments, treatment with PFAS generally
does not affect serum TSH levels [14,34]. When effectsFigure 1 Changes (%) in TSH level with increases in PFOS
quartiles. In the linear regression model, PFOS (ng/mL) was divided
into quartiles (Q1: ≤ 10.30; Q2: >10.30 and ≤13.09; Q3: >13.09 and
≤16.58; Q4: >16.58). Q1 was used as reference group and each quartile
was compared with the reference group. The model was adjusted for
maternal age, gestational age at blood draw, HDL concentrations, total
seafood intake, parity and inter-pregnancy interval.
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after dosing [17]. PFASs appear to displace thyroxine
from transthyretin, causing a transient increase in free
T4 [35]. The end effect may be a reduced total T4 with
adequate free T4 [14]. Data from animal models also
indicate other potential mechanisms by which PFAS
may affect thyroid hormone metabolism [34]. Thyroid
metabolism in rodents, however, is different than in
humans, partly because of transthyretin being a more
important transport protein in rodents. Furthermore,
during human pregnancy, human chorionic gonadotropin
and estrogen affect the TSH feedback mechanism [36],
further complicating comparison across species.
Compared with women from other western countries,
the median concentrations of PFOS and PFOA in this
study were slightly lower [21,37,38]. For TSH levels, the
median in our study was higher than that in other studies
of women in the second trimester [39,40]. The difference
may explained by the use of different immuno-metric
assays. TSH levels can differ by as much as 1.0 μIU/mL
because different monoclonal antibodies may recognize
different TSH isoforms circulating in the blood [36,41].
Iodine deficiency also affects TSH levels, but is rare in
Norway [42]. The prevalence of self-reported thyroid
disease in the present study (2.2%) was a little higher
than that among pregnant women in another recent study
from Norway [43].
We found concentrations of PFOA and PFHxS were
both correlated with PFOS, suggesting they might come
from common sources. However, they were not associated
with TSH levels statistically and PFOA showed a different
direction of association. These substances were usually
present lower at levels than PFOS, and have different
binding capacities with transthyretin due to different
structures [35].
The observed association between PFOS and TSH was
not present in the subfecund women. Although thyroid
disorders are related to reduced fertility [44], we did
not find a significant difference in TSH levels between
subfecund women and controls. Subfecundity may mask
the association, if any, between PFASs and TSH levels.
Our study had several limitations. Unfortunately, we
did not have access to sufficient plasma volume to perform
any other measurements of thyroid hormones, such as total
T4, free T4 and T3. TSH, however, is a sensitive marker
of thyroid status and reflects the physiologic log-linear
relationship of TSH to free T4 [36], and is often used by
itself in screening tests. Plasma TSH levels can reflect
mild thyroid functional impairment even when plasma T4
and T3 concentrations are within normal ranges [45].
Second, because our study was cross-sectional study,
reverse causation could affect the results. For example,
if low thyroid function led to reduced glomerular filtra-
tion rate [46], this could increase circulating PFASconcentrations [47]. Third, as TSH levels change during
pregnancy, a single measurement may not adequately
characterize thyroid homeostasis during pregnancy.
Fourth, although we considered some known potential
confounders, there may be unmeasured confounders not
taken into account. For example, the effects of other
chemicals, such as polychlorinated biphenyls (PCBs), on
TSH, can not be ruled out, given that fish intake is a
source of both PFASs and PCBs. Finally, the participation
rate in MoBa was low, raising the possibility of selection
bias. Nilsen et al. compared general characteristics, expo-
sures, pregnancy complications, and birth outcomes be-
tween MoBa participants and all women giving birth in
Norway and found differences in prevalence estimates
in most variables (Additional file 1: Table S1) [48]. For
the subjects in the present study we tabulated their
characteristics using the same format that Nilsen et al.
used (Additional file 1: Table S1). The present subjects were
generally similar to all MoBa participants, though some
minor differences were apparent, as would be expected due
to the subgroup sampled because of a long time-to-preg-
nancy. In spite of the differences between all women giving
birth in Norway and MoBa participants, Nilsen et al. found
estimates of exposure-outcome associations were similar
in the whole population and the MoBa participants [48],
and we expect this generalization holds for the present
analysis, in which inverse-sampling weights were used.Conclusions
Our results suggest an association between PFOS and
TSH in pregnant women that is small and maybe of no
clinical significance.Additional file
Additional file 1: Table S1. Background characteristics, pregnancy-
related exposures, and pregnancy complications [N(%)] for all women
giving birth in Norway, MoBa participants, and subjects in the present
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